Single-Particle Cryo-EM Lab
Model Cryo-EM 3D reconstruction, Fourier Shell Correlation (FSC 0.143), CTF Thon rings, Nyquist sampling, and Titan Krios facility DCF.
Optics & Data Parameters
Live SolverKrios Facility Budget
10-Yr Cash FlowFourier Shell Correlation (FSC) Resolution Curve
Gold-standard independent half-map correlation vs spatial frequencyContrast Transfer Function CTF(s) & Thon Ring Oscillations
Phase reversals and B-factor envelope damping as a function of defocus and spherical aberrationTitan Krios Core Facility — 5-Year Pro-Forma DCF
Comprehensive beamtime revenue, OEM service warranty, cryogen consumables, depreciation, and cash flows| Metric ($) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|
1. Relativistic Wavelength & Fourier Shell Correlation
High-energy electrons accelerated at 300 kV possess relativistic de Broglie wavelengths of only λ = 0.0197 Å:
The gold-standard FSC = 0.143 threshold compares two independent data halves. It corresponds to a true map-to-model correlation of 0.5, preventing noise over-fitting while providing an unbiased measure of reconstructed 3D resolution.
2. CTF Phase Reversals & Thon Rings
Weak phase contrast imaging requires objective lens defocus, introducing severe wave aberration oscillations:
Oscillations in CTF(s) produce alternating concentric rings of constructive and destructive interference (Thon rings). High-accuracy CTF estimation and phase-flipping are necessary to restore correct real-space electron density features.
3. Rosenthal-Henderson B-Factor Scaling
The number of particles required to achieve a target resolution d scales exponentially with the overall B-factor:
A sample with B = 50 Ų reaches 2.5 Šwith 50,000 particles, whereas a poorly vitrified or flexible specimen with B = 120 Ų requires millions of particles. Dose-fractionation movie alignment and energy filtration minimize beam-induced motion and lower experimental B-factors.
4. Core Facility Economics & Beamtime Yield
Cryo-EM has replaced X-ray crystallography as the dominant modality for membrane drug targets, GPCRs, and viral vaccines:
Operating a 300 kV Titan Krios on a continuous 24/7 schedule achieves high equipment utilization, generating strong operating margins that support expensive OEM warranty contracts while supplying structural insights for pharmaceutical pipelines.